Literature DB >> 26302185

Tissue factor pathway inhibitor gene transfer prevents vascular smooth muscle cell proliferation by interfering with the MCP-3/CCR2 pathway.

Yu Fu1, Dandan Ma1, Yue Liu1, Hui Li1, Jinyu Chi1, Wenxiu Liu1, Fang Lin1, Jing Hu2, Xiaohui Zhang1, Minling Zhu1, Yong Zhao3, Xinhua Yin1.   

Abstract

Increased vascular smooth muscle cell (VSMC) proliferation substantially contributes to the pathogenesis of atherosclerosis and intimal hyperplasia after vascular injury. The importance of inflammation in VSMC proliferation is now being recognized. Preventing the inflammatory response is one therapeutic strategy that can be used to inhibit atherosclerosis in the clinic. The present study, using RNA interference and gene transfer techniques, was conducted to investigate the effect of monocyte chemotactic protein-3 (MCP-3) on VSMC proliferation that is a result of TNF-α stimulation, and whether overexpression of the tissue factor pathway inhibitor (TFPI) gene could prevent VSMC proliferation by blocking the MCP-3/CC chemokine receptor 2 (CCR2) pathway. Mouse VSMCs were infected in vitro with recombinant adenoviruses containing either mouse MCP-3-shRNA (Ad-MCP-3-shRNA), the TFPI gene (Ad-TFPI), or the negative control, which was shRNA encoding the sequence for EGFP (Ad-EGFP) or DMEM only. The cells were then stimulated with TNF-α for different time periods on the third day after gene transfer. The data show that VSMC proliferation in the Ad-MCP-3-shRNA and Ad-TFPI groups was markedly decreased using BrdU ELISA and MTT assays; MCP-3-shRNA and TFPI inhibited the expression of MCP-3 and CCR2 after long-term stimulation and inhibited the phosphorylation of ERK1/2 and AKT after short-term stimulation, as shown by ELISA and western blot analysis. This study provides convincing evidence that clarifies the effect of the proinflammatory factor MCP-3 in promoting VSMC proliferation. Our data also show, for the first time, that TFPI has an anti-proliferative role in TNF-α stimulated-VSMCs at least partly by interfering with the MCP-3/CCR2 pathway and then via suppression of the ERK1/2 and PI3K/AKT signaling pathways. We conclude that TFPI gene transfer may be a safe and effective therapeutic tool for treating atherosclerosis and intimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26302185     DOI: 10.1038/labinvest.2015.106

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  39 in total

Review 1.  Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies.

Authors:  Victor J Dzau; Ruediger C Braun-Dullaeus; Daniel G Sedding
Journal:  Nat Med       Date:  2002-11       Impact factor: 53.440

2.  The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis.

Authors:  Ioana Madalina Fenyo; Anca Violeta Gafencu
Journal:  Immunobiology       Date:  2013-06-19       Impact factor: 3.144

3.  Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling.

Authors:  Katharina Lötzer; Sandra Döpping; Sabine Connert; Rolf Gräbner; Rainer Spanbroek; Birgit Lemser; Michael Beer; Markus Hildner; Thomas Hehlgans; Michael van der Wall; Reina E Mebius; Agnes Lovas; Gwendalyn J Randolph; Falk Weih; Andreas J R Habenicht
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-02-05       Impact factor: 8.311

4.  Reversal of vascular macrophage accumulation and hypertension by a CCR2 antagonist in deoxycorticosterone/salt-treated mice.

Authors:  Christopher T Chan; Jeffrey P Moore; Klaudia Budzyn; Elizabeth Guida; Henry Diep; Antony Vinh; Emma S Jones; Robert E Widdop; James A Armitage; Samy Sakkal; Sharon D Ricardo; Christopher G Sobey; Grant R Drummond
Journal:  Hypertension       Date:  2012-10-01       Impact factor: 10.190

5.  The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice.

Authors:  Gianluca Grassia; Marcella Maddaluno; Angelo Guglielmotti; Giorgina Mangano; Giuseppe Biondi; Pasquale Maffia; Armando Ialenti
Journal:  Cardiovasc Res       Date:  2009-07-10       Impact factor: 10.787

Review 6.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

7.  Chemokine receptor expression and in vivo signaling pathways in the joints of rats with adjuvant-induced arthritis.

Authors:  Shiva Shahrara; Mohammad A Amin; James M Woods; G Kenneth Haines; Alisa E Koch
Journal:  Arthritis Rheum       Date:  2003-12

8.  HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries.

Authors:  Xinhua Yin; Yu Fu; Chikao Yutani; Yoshihiko Ikeda; Keiichi Enjyoji; Hisao Kato
Journal:  Int J Cardiol       Date:  2008-06-30       Impact factor: 4.164

9.  Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty.

Authors:  Yoichi Nakamura; Kazufumi Nakamura; Keiko Ohta; Hiromi Matsubara; Chikao Yutani; Tsutomu Hamuro; Hisao Kato; Tohru Ohe
Journal:  Basic Res Cardiol       Date:  2002-05       Impact factor: 17.165

10.  Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice.

Authors:  Xiao Ling Liu; Peng Fei Zhang; Shi Fang Ding; Yan Wang; Mei Zhang; Yu Xia Zhao; Mei Ni; Yun Zhang
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

View more
  6 in total

1.  Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer.

Authors:  Xiaoli Ren; Jianbiao Xiao; Wanning Zhang; Feifei Wang; Yongrong Yan; Xuehui Wu; Zhicheng Zeng; Yumei He; Wei Yang; Wangjun Liao; Yanqing Ding; Li Liang
Journal:  Cell Death Dis       Date:  2021-05-13       Impact factor: 8.469

2.  Crosstalk between CCL7 and CCR3 promotes metastasis of colon cancer cells via ERK-JNK signaling pathways.

Authors:  Yeo Song Lee; So-Young Kim; Su Jeong Song; Hye Kyung Hong; Yura Lee; Bo Young Oh; Woo Yong Lee; Yong Beom Cho
Journal:  Oncotarget       Date:  2016-06-14

3.  Irisin promotes C2C12 myoblast proliferation via ERK-dependent CCL7 upregulation.

Authors:  Jangho Lee; Joon Park; Young Ho Kim; Nam Hyouck Lee; Kyung-Mo Song
Journal:  PLoS One       Date:  2019-09-13       Impact factor: 3.240

4.  Spherical silica nanoparticles promote malignant transformation of BEAS-2B cells by stromal cell-derived factor-1α (SDF-1α).

Authors:  Chong Guo; Ding-Yun You; Huan Li; Xiao-Yu Tuo; Zi-Jie Liu
Journal:  J Int Med Res       Date:  2019-02-07       Impact factor: 1.671

Review 5.  CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease.

Authors:  Ting-Ting Chang; Ching Chen; Jaw-Wen Chen
Journal:  Cardiovasc Diabetol       Date:  2022-09-15       Impact factor: 8.949

6.  Common dysregulated pathways in obese adipose tissue and atherosclerosis.

Authors:  V Moreno-Viedma; M Amor; A Sarabi; M Bilban; G Staffler; M Zeyda; T M Stulnig
Journal:  Cardiovasc Diabetol       Date:  2016-08-26       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.